NASDAQ: ESTAEstablishment Labs Holdings Inc Stock
$47.38-5.19 (-9.87%)
Updated Apr 19, 2024
ESTA Price
$47.38
Fair Value Price
N/A
Market Cap
$1.29B
52 Week Low
$16.96
52 Week High
$77.55
P/E
-15.43x
P/B
70.07x
P/S
4.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$165.15M
Earnings
-$78.50M
Gross Margin
64.8%
Operating Margin
-38.26%
Profit Margin
-47.5%
Debt to Equity
13.6
Operating Cash Flow
-$89M
Beta
1.24
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ESTA Overview
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ESTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ESTA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ESTA is poor value based on its book value relative to its share price (70.07x), compared to the US Medical Devices industry average (3.63x)
P/B vs Industry Valuation
ESTA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ESTA due diligence checks available for Premium users.
Be the first to know about important ESTA news, forecast changes, insider trades & much more!
ESTA News
Valuation
ESTA fair value
Fair Value of ESTA stock based on Discounted Cash Flow (DCF)
Price
$47.38
Fair Value
$37.04
Overvalued by
27.91%
ESTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ESTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-15.43x
Industry
28.69x
Market
40.51x
ESTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
70.07x
Industry
3.63x
ESTA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ESTA's financial health
Profit margin
Revenue
$31.6M
Net Income
-$20.5M
Profit Margin
-65.1%
ESTA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ESTA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$268.6M
Liabilities
$250.2M
Debt to equity
13.6
ESTA's short-term assets ($174.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ESTA's long-term liabilities ($193.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ESTA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ESTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.1M
Investing
-$4.6M
Financing
$65.0k
ESTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ESTA vs Medical Device Stocks
Establishment Labs Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.